Pemazyre(pemigatinib)
Pemazyre (pemigatinib) is a small molecule pharmaceutical. Pemigatinib was first approved as Pemazyre on 2020-04-17. It is used to treat cholangiocarcinoma in the USA. It has been approved in Europe to treat cholangiocarcinoma. It is known to target fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, and fibroblast growth factor receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Pemazyre
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pemazyre | New Drug Application | 2023-06-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cholangiocarcinoma | — | D018281 | C22.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PEMIGATINIB, PEMAZYRE, INCYTE CORP | |||
| 2029-08-26 | ODE-404 | ||
| 2027-04-17 | ODE-292 | ||
| 2025-08-26 | I-899 | ||
| 2025-04-17 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cholangiocarcinoma | D018281 | — | C22.1 | 3 | 7 | 1 | — | — | 10 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 4 | 13 | — | — | — | 16 |
| Carcinoma | D002277 | — | C80.0 | — | 7 | — | — | — | 7 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 5 | — | — | 1 | 6 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 4 | — | — | 1 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 4 | — | — | — | 4 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | 4 | — | — | — | 4 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 4 | — | — | — | 4 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 3 | — | — | — | 3 |
| Transitional cell carcinoma | D002295 | — | — | — | 3 | — | — | — | 3 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 2 | — | — | — | 2 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pemigatinib |
| INN | pemigatinib |
| Description | Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21 |
Identifiers
| PDB | — |
| CAS-ID | 1513857-77-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297522 |
| ChEBI ID | — |
| PubChem CID | 86705695 |
| DrugBank | DB15102 |
| UNII ID | Y6BX7BL23K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
FGFR1
FGFR1
FGFR3
FGFR3
FGFR2
FGFR2
Organism
Homo sapiens
Gene name
FGFR1
Gene synonyms
BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR
NCBI Gene ID
Protein name
fibroblast growth factor receptor 1
Protein synonyms
Basic fibroblast growth factor receptor 1, bFGF-R-1, BFGFR, CD331, FGFR1/PLAG1 fusion, FLT-2, FMS-like tyrosine kinase 2, fms-related tyrosine kinase 2, heparin-binding growth factor receptor, hydroxyaryl-protein kinase, N-sam, Proto-oncogene c-Fgr
Uniprot ID
Mouse ortholog
Fgfr1 (14182)
fibroblast growth factor receptor 1 (Q9QZM7)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Pemazyre – Incyte
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,282 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
575 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use